DSM-Firmenich stock holds steady as 2025 results show higher profit

DSM-Firmenich (CH1216478797) is anchored by its 2025 numbers: revenue reached EUR 12.82 billion, adjusted EBITDA was EUR 2.13 billion, and reported net profit came in at EUR 420 million. Those figures give DSM-Firmenich stock a concrete earnings base even without a fresh market catalyst.

EUR 12.82 billion revenue

In the companys 2025 annual reporting, revenue was EUR 12.82 billion and adjusted EBITDA was EUR 2.13 billion, while reported net profit totaled EUR 420 million. The EBITDA margin was therefore about 16.6%, a useful margin reference for the stock narrative.

The comparison matters: those numbers show a large-scale specialty ingredients business that still converts sales into profit, and the EUR 420 million net result gives the market a simple reference point for earnings power.

Margin and profit base

DSM-Firmenich also reported EUR 2.13 billion of adjusted EBITDA against EUR 12.82 billion of revenue, which implies a 16.6% margin in 2025. For investors, that ratio matters because it links volume growth, pricing and cost control to the equity story.

The EUR 420 million reported net profit adds a second earnings anchor. Together with the revenue figure, it shows how DSM-Firmenich stock can be read through both top-line scale and bottom-line conversion.

Nutrition and ingredients

The companys business is built around nutrition, health and ingredients, and that structure is reflected in the 2025 profit profile. The latest annual figures show why the stock is often judged on margin quality rather than on revenue alone.

Stock level and valuation

Because no dated quote was available in the search results for this call, the cleanest market reference is the 2025 earnings base itself: EUR 12.82 billion revenue, EUR 2.13 billion adjusted EBITDA and EUR 420 million reported net profit. Those numbers set the valuation backdrop for DSM-Firmenich stock ahead of the next reporting update.